Initial Empiric Antibiotic Therapy for Hospital-Acquired Pneumonia (HAP)

Risk Stratification for HAP Treatment

For patients with hospital-acquired pneumonia, empiric antibiotic therapy should be stratified based on risk factors for multidrug-resistant (MDR) pathogens and mortality risk, with prompt initiation of appropriate broad-spectrum antibiotics tailored to local resistance patterns 1, 2
The Infectious Diseases Society of America (IDSA) recommends using one of the following monotherapy options for patients not at high risk of mortality and no risk factors for MRSA: Piperacillin-tazobactam 4.5 g IV q6h, Cefepime 2 g IV q8h, Imipenem 500 mg IV q6h, or Meropenem 1 g IV q8h 2, 3
For patients not at high risk of mortality but with risk factors for MRSA, the IDSA recommends adding MRSA coverage with Vancomycin 15 mg/kg IV q8-12h or Linezolid 600 mg IV q12h 1, 2, 3

Prompt administration of empiric antibiotics is critical as delays in appropriate therapy are associated with increased mortality 5, 6
The American Thoracic Society (ATS) recommends basing empiric regimens on local distribution of pathogens and their antimicrobial susceptibilities 1, 2
All hospitals should regularly generate and disseminate a local antibiogram tailored to their HAP population 1

For patients with structural lung disease, the IDSA recommends two antipseudomonal agents 1
If ESBL-producing organisms or Acinetobacter species are suspected, a carbapenem is a reliable choice 8
If Legionella pneumophila is suspected, the ATS recommends including a macrolide or fluoroquinolone rather than an aminoglycoside 8